A systematic review and meta-analysis of shRNA-IL-6-engineered CAR-T cells for B-cell acute lymphoblastic leukemia: a stepping stone toward risk-free immunotherapy. This evidence concerns the gene IL6 and B-cell acute lymphoblastic leukemia.